Compare BWMN & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWMN | CSTL |
|---|---|---|
| Founded | 1995 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 579.7M | 661.7M |
| IPO Year | 2021 | 2019 |
| Metric | BWMN | CSTL |
|---|---|---|
| Price | $35.87 | $39.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $41.13 | $40.67 |
| AVG Volume (30 Days) | 133.5K | ★ 461.5K |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $474,277,000.00 | $343,530,000.00 |
| Revenue This Year | $16.97 | $1.69 |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | $38.71 | ★ N/A |
| Revenue Growth | ★ 16.73 | 10.15 |
| 52 Week Low | $17.90 | $14.59 |
| 52 Week High | $45.83 | $40.61 |
| Indicator | BWMN | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 51.14 | 69.78 |
| Support Level | $33.15 | $36.63 |
| Resistance Level | $36.39 | $40.54 |
| Average True Range (ATR) | 1.66 | 1.31 |
| MACD | 0.48 | -0.48 |
| Stochastic Oscillator | 77.42 | 60.55 |
Bowman Consulting Group Ltd is a professional services firm delivering engineering solutions to customers who own, develop, and maintain the built environment. It provides planning, engineering, construction management, commissioning, environmental consulting, geospatial, survey, land procurement, and other technical services to customers operating in a diverse set of end markets. Its services include Civil & Site Engineering, Transportation Engineering, MEP Engineering, Commissioning & Energy Efficiency, Energy Services, Water/Wastewater, Fire Protection, Construction Management, Survey/Geospatial, Environmental Consulting, Structural Engineering, Land Procurement & Right-of-Way, Landscape and Architecture/Planning.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.